ANI Pharmaceuticals (ANIP) Receives Daily News Impact Rating of 0.04
Press coverage about ANI Pharmaceuticals (NASDAQ:ANIP) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ANI Pharmaceuticals earned a news impact score of 0.04 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.7377485233384 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
ANIP has been the topic of a number of recent analyst reports. TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, November 16th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a report on Tuesday, November 7th. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 4th. Canaccord Genuity reissued a “buy” rating on shares of ANI Pharmaceuticals in a research report on Thursday, November 2nd. Finally, BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $71.00.
Shares of ANI Pharmaceuticals (NASDAQ ANIP) opened at $70.32 on Wednesday. ANI Pharmaceuticals has a 1 year low of $42.23 and a 1 year high of $74.70. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45. The firm has a market capitalization of $842.51, a P/E ratio of 109.88 and a beta of 2.90.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Stock Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related stocks with our FREE daily email newsletter.